Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir: Findings From the Antiretroviral Pregnancy Registry.
BACKGROUND: Safe and effective antiretrovirals (ARVs) are essential for managing HIV-1 in pregnant individuals and ensuring positive pregnancy outcomes. International guidelines recommend dolutegravir-based regimens as the preferred option for pregnant individuals or those planning to conceive. SETTING: The Antiretroviral Pregnancy Registry (APR) is a voluntary, international, prospective, exposure-registration cohort study providing early warning signals of major teratogenicity with ARV use. METHODS: Pregnancy and neonatal outcomes following prenatal dolutegravir exposure were assessed among prospectively reported pregnancies starting in 2013, after dolutegravir approval for HIV-1 treatment, through January 31, 2025. Birth defect prevalence after first-trimester dolutegravir exposure was compared with prevalence during the second and third trimesters, for other ARVs, and the general US population. RESULTS: Among 2075 pregnancies exposed to dolutegravir, initial exposure occurred during periconception, later first trimester, second trimester, and third trimester in 53%, 14%, 24%, and 9% of pregnancies, respectively. Overall, 93% (1970/2127) of pregnancy outcomes resulted in live births. Birth defect prevalence after first-trimester dolutegravir exposure was 3.3% (95% CI, 2.4%-4.4%), which was comparable to rates for other ARVs and the general US population. A single neural tube defect (anencephaly) was reported among pregnancies with earliest dolutegravir exposure during periconception, corresponding to a prevalence of 0.1% (1/1120). Among the 1802 singleton live births without defects, 89% (n=1605) were delivered at ≥37 weeks of gestation, and 85% (n=1540) had a birth weight ≥2500 g. CONCLUSION: Findings confirm the safety of prenatal dolutegravir exposure and reinforce dolutegravir-based regimens as safe options for all people of childbearing potential.
Authors
- Michelle Kisare (ORCID: https://orcid.org/0009-0004-9413-5295)
- William R. Short (ORCID: https://orcid.org/0000-0003-4225-8336)
- Karen Beckerman
- Hugh H. Tilson (ORCID: https://orcid.org/0000-0001-8074-658X)
- Vani X. Vannappagari (ORCID: https://orcid.org/0000-0002-0157-9689)
- Angela E. Scheuerle (ORCID: https://orcid.org/0000-0002-9025-3276)
- Jessica D. Albano (ORCID: https://orcid.org/0000-0003-2202-1198)
- Lynne Mofenson
- Claire Thorne
- Leigh Ragone
- Nicole Carneal-Frazer
- Taylor Cook
- Annemiek de Ruiter
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2026-11-18
- DOI
- https://doi.org/10.17615/58j9-e482
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00